Lumicell

06/01/2026

Adjuvant therapy and post surgical treatments are critical in the fight against cancer—but surgery remains the foundation.

What happens in the OR can shape everything that follows.

That’s why real time intraoperative insight matters. By providing actionable information at the point of care, LumiSystem helps surgeons identify and remove residual cancer when it matters most—during the initial procedure.

In the Pivotal study, LumiSystem helped guide the removal of residual tumors, including sizeable disease up to 13 mm, contributing to improved surgical outcomes for 1 in 10 patients*.

Learn more at https://lumisystem.com/

* Smith et al., NEJM Evidence 2, no. 7 (June 27, 2023)

05/28/2026

We're thrilled to announce the promotion of Marnie Curbow to Chief Commercial Officer at Lumicell!🎉

Since joining in October 2025 as Vice President of Sales, Marnie has built our commercial organization from the ground up: leading sales, marketing, reimbursement, and now clinical applications. Her leadership has been instrumental in shaping our go-to-market strategy as we advance our fluorescence-guided breast surgery platform.

Congratulations, Marnie — you earned this. Thank you for bringing the light to our customers and team every day!

05/25/2026

This Memorial Day, we honor and remember those who gave their lives in service to our country.

At Lumicell, we’re grateful for their courage and sacrifice—and for the freedoms they protect. Their service inspires us every day as we work to improve the lives of patients and those who care for them.

Wishing you a meaningful and reflective Memorial Day.

05/18/2026

DCIS can extend beyond what imaging and specimen-based tools can reveal, making margin assessment especially challenging. Residual disease may remain because traditional intraoperative methods can’t directly visualize what remains in the breast cavity.

LumiSystem® is the first and only technology designed to illuminate suspected residual cancer in the breast cavity in real-time, giving surgeons added insight to address risk of positive margins and re-excision.

Learn more https://lumisystem.com/

05/11/2026

Confidence matters when moving forward with oncoplastic technique. Real-time visualization of suspected residual cancer can help surgeons navigate some of the challenges in oncoplastic breast-conserving surgery.

LumiSystem® illuminates suspected residual cancer in the breast cavity to help support more informed surgical decisions when it matters most.

Learn more https://lumisystem.com/

04/28/2026

ASBrS 2026 is nearly here and we can’t wait to connect in Seattle! ✈️🏙️🤝

🩺 ASBrS 2026
📅 April 29-May 3

Don’t forget…there are plenty of ways to engage with us while there!

-Visit us at Booth 423 to see the technology live and race your colleagues to .

-Meet our Leadership team at our booth or over a relaxed evening dinner event.

-Bonus for Breast Fellows – We’ll be at The Fellows Workshop on Thursday April 30 with hands-on demonstrations of our technology.

See you in Seattle!

04/22/2026

Now live 🎥

We’re proud to share Lumicell’s feature on Health Uncensored with Dr. Drew!

The segment focuses on the challenges surgeons face in identifying residual cancer during lumpectomy procedures and the potential impact of enhanced intraoperative visualization.

Watch here: https://www.youtube.com/watch?v=86LUsJhMhJE

Important Safety Information:
The most common side effects with LUMISIGHT(TM) (pegulicianine) are hypersensitivity and an abnormal color in urine. LUMISIGHT may cause serious hypersensitivity reactions, including anaphylaxis. Please see the LUMISIGHT Prescribing Information (https://lumisystem.com/prescribing-information/), including Boxed Warning, and Lumicell DVS Instructions for Use (https://lumisystem.com/instructions-for-use/) . For complete product information, visit www.LumiSystem.com.

1 like. "Changing the Face of Surgical Oncology"

04/14/2026

We’re excited to share that Lumicell will be featured on Health Uncensored with Dr. Drew, discussing advances in breast cancer surgery and the role of enhanced intraoperative visualization.

The segment, “Transforming Cancer Surgery,” features Dr. Fedra Fallahian, breast surgical oncologist, Jorge Ferrer PhD, Lumicell’s Chief Scientific Officer, and Kristie Cole, breast cancer patient, in an in-studio conversation focused on surgical decision making and the patient experience.

📺 Tune in April 19th at 5:00PM ET on Fox Business!

04/10/2026

We are heading to Seattle for ASBrS2026 and look forward to connecting with attendees!
📅 April 29-May 3

Lumicell is planning lots of opportunities to engage – join us!

Visit our Booth 423 for a hands-on demo and interactive experience featuring LumiSystem® the only intraoperative technology that illuminates suspected residual cancer in the breast cavity.

Meet our Leadership team, including our VP of Innovation, VP of Sales, and VP of Research & Development for meaningful scientific discussions. Plus, join them for relaxed clinical conversation over dinner Friday May 1 or Saturday May 2.

Attend our curated elegant dinner presentation Intraoperative Insights: A Clinical Dinner Discussion, Thursday April 30, featuring Dr. Fallahian.

Bonus for Breast Fellows! We are sponsoring The Fellows Workshop Thursday April 30, 7am-3:30pm and will be onsite with hands-on demos. Catch us there!

Let’s meet in Seattle!

03/31/2026

Surgeons use imaging and localization tools to guide lumpectomy, but cannot see what may remain in the breast cavity or confirm clear margins in real-time. Confirmation comes days later with pathology results.

LumiSystem™ is the first and only intraoperative technology that helps visualize suspected residual cancer to inform surgical decisions when it matters most.

Learn more at
https://lumisystem.com/